Loading…
Cybin D/B/A Helus Pharma is projected to rise to $9.46 by 2027, a +38% move from its current price of $6.87. HELP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $6.59 | $6.88 | $7.17 | +0.11% |
| Jul 14 | $6.49 | $6.89 | $7.31 | +0.23% |
| Jul 15 | $6.41 | $6.89 | $7.41 | +0.34% |
| Jul 16 | $6.35 | $6.90 | $7.51 | +0.46% |
| Jul 17 | $6.29 | $6.91 | $7.59 | +0.57% |
| Jul 18 | $6.24 | $6.92 | $7.67 | +0.69% |
| Jul 19 | $6.20 | $6.93 | $7.74 | +0.81% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.20 | $6.93 | $7.74 | +0.81% |
| Week 2 | $5.97 | $6.98 | $8.17 | +1.62% |
| Week 3 | $5.80 | $7.04 | $8.53 | +2.44% |
| Week 4 | $5.68 | $7.09 | $8.86 | +3.26% |
| Week 5 | $5.58 | $7.15 | $9.17 | +4.09% |
| Week 6 | $5.49 | $7.21 | $9.47 | +4.93% |
| Week 7 | $5.41 | $7.27 | $9.75 | +5.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cybin Inc., doing business as Helus Pharma, is a clinical-stage neuropsychiatry company. It focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
Helus Pharma develops CYB003, a deuterated psilocybin analog, in phase 3 clinical trials to treat major depressive disorder. CYB004, a deuterated N, N-dimethyltryptamine (DMT), is in phase 2 clinical trials for generalized anxiety disorders. It also develops SPL028 injectable deuterated DMT (completed phase 1), SPL026 for MDD, and CYB005 in preclinical stage, with a research pipeline of investigational psychedelic-based compounds.
The company is headquartered in Toronto, Canada.
HELP (Cybin D/B/A Helus Pharma) trades under the symbol HELP. The current price is $6.63.
The market cap is $410.95M and the company is ranked 3225 by market capitalization.
The year-by-year forecast points to upside across the horizon, with 2026 showing an average price of $6.63 and a neutral sentiment, followed by bullish momentum in later years. The 2027 average is $9.11, 2030 average $10.74, 2040 average $29.29, and 2050 average $65.25, with corresponding ROIs of 37.4%, 62%, 341.8%, and 884.1% respectively.
Overall, the outlook across the multi-year horizon is bullish, reflecting meaningful potential upside while acknowledging that these are estimates, not guarantees.
A major floor 58.3% below — a decisive break under it would weaken the trend.
The nearest floor, 43.7% below — buyers have tended to step in here.
Price is pressing into resistance (0.1% away) — a breakout level to watch.
A major ceiling 29.3% above — clearing it would confirm fresh momentum.
Key HELP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HELP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.33 | Buy | $6.49 | Buy |
| MA 10 | $6.41 | Buy | $6.23 | Buy |
| MA 20 | $5.55 | Buy | $5.78 | Buy |
| MA 50 | $5.05 | Buy | $5.36 | Buy |
| MA 100 | $5.36 | Buy | $5.48 | Buy |
| MA 200 | $5.98 | Buy | $5.99 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 70.26 | Sell |
| Stoch RSI (14) | 53.31 | Neutral |
| CCI (20) | 96.79 | Neutral |
| Williams %R (14) | -0.49 | Info |
| MACD (12,26,9) | 0.10 | Buy |
| ROC (12) | 41.65 | Buy |
| Bollinger %B (20,2) | 0.84 | Neutral |
| Stochastic %K (14) | 99.51 | Sell |
| TRIX (15) | 1.22 | Buy |
| Awesome (5,34) | 1.27 | Buy |
| Ultimate (7,14,28) | 64.52 | Neutral |
| Momentum (10) | 0.85 | Buy |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 6.49 | Buy |
| ADX (14) | 28.15 | Buy |
| ATR (14) | 0.24 | Info |
The 30-day technical picture is bullish. RSI(14) is 70, indicating strong near-term momentum. The near-term trend is supported by a price framework that includes the 50-day moving average at $5.01 and the 200-day moving average at $5.98.
Key support sits at $3.87, with resistance at $6.88, providing a clear path for near-term price action. The 30-day price range runs from $5.00 to $8.79, highlighting a relatively wide swing in the recent month. Annualized volatility is 80%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.87 | $6.87 | $10.16 | 0% | Neutral | |
| $7.15 | $9.46 | $13.43 | +38% | Bullish | |
| $6.91 | $9.56 | $14.31 | +39% | Bullish | |
| $7.23 | $10.39 | $16.21 | +51% | Bullish | |
| $7.56 | $11.26 | $18.15 | +64% | Bullish | |
| $7.55 | $11.60 | $19.26 | +69% | Bullish | |
| $10.76 | $17.03 | $29.04 | +148% | Bullish | |
| $12.00 | $19.56 | $34.14 | +185% | Bullish | |
| $10.60 | $17.75 | $31.66 | +158% | Bullish | |
| $11.28 | $19.40 | $35.29 | +182% | Bullish | |
| $15.77 | $30.71 | $60.65 | +347% | Bullish | |
| $30.84 | $68.54 | $152.14 | +898% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.87 | $6.87 | $8.28 | +0.00% |
| August 2026 | $6.03 | $7.22 | $8.95 | +5.05% |
| September 2026 | $6.30 | $7.63 | $9.62 | +5.68% |
| October 2026 | $6.16 | $7.52 | $9.62 | -1.35% |
| November 2026 | $6.04 | $7.44 | $9.62 | -1.10% |
| December 2026 | $6.26 | $7.77 | $10.16 | +4.41% |
Click any year to see its month-by-month HELP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, HELP could reach as high as $10.16, with a base case around $6.87 and support toward $3.87 — roughly 0% from $6.87. Price action looks broadly range-bound.
Expect HELP to range from $7.15 to $13.43 through 2027. The $9.46 average target implies a +38% move from current prices. That is up +38% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The HELP price prediction for 2028 points to an average of $9.56 (low $6.91, high $14.31) — a potential gain of +39% on today's $6.87. Momentum favours further upside here.
In 2029, HELP is projected to trade between $7.23 and $16.21, averaging $10.39 — a potential gain of +51% from today's $6.87. That is up +9% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Cybin D/B/A Helus Pharma's 2030 outlook centres on $11.26, within a $7.56 to $18.15 range. That is up +8% on the projected 2029 average. That marks a +64% change versus current levels. Momentum favours further upside here.
By 2031, HELP could reach as high as $19.26, with a base case around $11.60 and support toward $7.55 — roughly +69% from $6.87. Buyers look set to stay in control over this stretch.
Expect HELP to range from $10.76 to $29.04 through 2032. The $17.03 average target implies a +148% move from current prices. That is up +47% on the projected 2031 average. Momentum favours further upside here.
The HELP price prediction for 2033 points to an average of $19.56 (low $12.00, high $34.14) — a potential gain of +185% on today's $6.87. Buyers look set to stay in control over this stretch.
In 2034, HELP is projected to trade between $10.60 and $31.66, averaging $17.75 — a potential gain of +158% from today's $6.87. That is -9% versus the projected 2033 average. Momentum favours further upside here.
Cybin D/B/A Helus Pharma's 2035 outlook centres on $19.40, within a $11.28 to $35.29 range. That is up +9% on the projected 2034 average. That marks a +182% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, HELP could reach as high as $60.65, with a base case around $30.71 and support toward $15.77 — roughly +347% from $6.87. Momentum favours further upside here.
Expect HELP to range from $30.84 to $152.14 through 2050. The $68.54 average target implies a +898% move from current prices. That is up +123% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in HELP today (≈ 145.560408 HELP) could be worth
$9,976.92
+$8,976.92 (+898%) by 2050 · US Dollar
Based on the average projected HELP price of $68.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HELPwould be worth at today's price.
$1,000 invested in HELP on Jul 10, 2025 (≈ 131.578949 HELP) would be worth
$903.95
-$96.05 (-9.6%) today · 0.90× · US Dollar
Based on a HELP entry price of $7.6 vs. today's $6.87.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.24 | $1,100.96 | +10.1% |
| 1 month ago | $3.87 | $1,775.19 | +77.5% |
| 3 months ago | $5.22 | $1,316.09 | +31.6% |
| 6 months ago | $7.38 | $930.89 | -6.9% |
| 1 year ago | $7.6 | $903.95 | -9.6% |
| All time (5.0y) ago | $102.6 | $66.96 | -93.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HELP forecast.
Our base-case forecast reaches $14.00 around 2032.
Implied market cap at $14.00: $867.78M
The multi-year forecast shows a pronounced upside from 2026 through 2050. The 2026 average price is $6.63 with a 0% ROI, then rising to an average of $9.11 in 2027 (ROI 37.4%). By 2030, the average is $10.74 with a 62% ROI. The forecast continues higher, with 2040 averaging $29.29 and a 341.8% ROI, and 2050 averaging $65.25 with an 884.1% ROI.
Beyond 2030, the trajectory remains bullish, with 2032 averaging $16.38 (ROI 147.1%), 2033 at $18.72 (ROI 182.3%), 2034 at $16.95 (ROI 155.7%), and 2035 at $18.56 (ROI 179.9%). These figures illustrate substantial upside potential over the long term, albeit with the usual uncertainty attached to forecasts.
These are estimates and not guarantees; actual results will depend on a range of factors including clinical outcomes, regulatory decisions, and broader market conditions.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $10.74, with a minimum of $7.18 and a maximum of $17.41. The ROI is projected at 62%, and the sentiment is BULLISH.
The forecast indicates upside with a 2027 average of $9.11 (ROI 37.4%) and a 2030 average of $10.74 (ROI 62%). These are estimates, not guarantees, and depend on future developments in the company’s clinical programs and market conditions.
Yes, the forecast shows a 2050 maximum of $145.94, with an average of $65.25, implying that higher price levels beyond $100 are possible in the long term according to the projections, though such outcomes are not guaranteed.
Current price is $6.63 and market cap is $410.95M.
The 30-day range is $5.00 to $8.79, with RSI(14) at 70, SMA50 at $5.01, SMA200 at $5.98, support at $3.87, and resistance at $6.88. Annualized volatility is 80%.
Cybin D/B/A Helus Pharma Community Discussion
0Share your Cybin D/B/A Helus Pharma price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.